scPharmaceuticals Inc. (SCPH)

Price Chart

scPharmaceuticals Inc. (SCPH) stock price: $5.67 (+0.00, +0.00%)

Why Bull

• •Recent insider buying suggests confidence in SCPH's future prospects, indicating that those with the most knowledge believe in the company's potential.
• •Community sentiment has shifted positively, with discussions around SCPH's innovative pipeline gaining traction among investors.
• •Recent partnerships and collaborations have strengthened SCPH's market position, showcasing its commitment to growth and development.
• •Positive media coverage has highlighted SCPH's advancements, increasing visibility and attracting interest from a broader investor base.

Why Bear

• •Concerns have arisen regarding SCPH's ability to meet regulatory hurdles, leading to skepticism among some investors about its future success.
• •Social sentiment has shown a rise in bearish comments, with some community members expressing doubts about the sustainability of SCPH's recent gains.
• •Market perception has been clouded by broader economic uncertainties, causing investors to be cautious about new positions in SCPH.
• •Recent earnings reports have not met expectations, leading to a reevaluation of SCPH's growth narrative among analysts and investors.

• Earnings Scheduled For August 7, 2025
  benzinga · Aug 7, 2025
• Earnings Scheduled For May 14, 2025
  benzinga · May 14, 2025
• Earnings Scheduled For November 9, 2022
  benzinga · Nov 9, 2022

Rationale

AI-generated technical analysis for SCPH including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Set your price target for scPharmaceuticals Inc. (SCPH), choose a timeframe, and track your prediction accuracy.

Current price: $5.67

No insider trades in the last 30 days.

Score Factors

• Revenue Growth 5/100

  Revenue growth data is currently unavailable for this company.

• Gross Margin 5/100

  Gross margin data is currently unavailable for this company.

• Operating Leverage 4/100

  Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.

• Cash Runway 5/100

  Cash position data is currently unavailable for this company.

• R&D Intensity 5/100

  R&D spending data is currently unavailable for this company.

• Insider Activity 6/100

  No significant insider buying or selling recently, which is neutral for the stock outlook.

• Short Interest 5/100

  Float and volume data unavailable for liquidity analysis.

• Price Momentum 0/100

  No bullish technical signals detected. The stock lacks upward price momentum currently.

• News Sentiment 5/100

  No sentiment data available

What does this score mean?

The MoonshotScore rates SCPH's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

What does scPharmaceuticals Inc. do?

scPharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative pharmaceutical products, primarily utilizing subcutaneous drug delivery technology. Their lead product, FUROSCIX, is designed to treat fluid overload in heart failure patients by providing a convenient, at-home alternative to intravenous diuretics. The company is also developing scCeftriaxone and scCarbapenem, both antibiotics, to combat bacterial infections. By focusing on innovative drug delivery methods, scPharmaceuticals aims to improve patient outcomes and reduce healthcare costs associated with chronic diseases and infections.

Is SCPH stock a good buy?

Evaluating SCPH requires considering both its potential and risks. The company's innovative FUROSCIX product addresses a significant unmet need in heart failure treatment, potentially driving substantial revenue growth. The 68.5% gross margin suggests strong pricing power. However, SCPH is currently unprofitable, with a negative profit margin of -183.5%, and relies heavily on the success of FUROSCIX. Investors should weigh the potential upside of FUROSCIX against the company's financial challenges and competitive landscape before making an investment decision. Further data is needed to assess the long-term viability.

What are the main risks for SCPH?

scPharmaceuticals faces several key risks. A primary risk is its dependence on the success of FUROSCIX, as the company's revenue stream is heavily reliant on this single product. Regulatory setbacks or delays in obtaining approvals for FUROSCIX or other pipeline products could significantly impact the company's financial performance. Competition from established pharmaceutical companies with greater resources and broader product portfolios also poses a threat. Additionally, the company's negative profitability and need for additional financing could create financial strain and dilute shareholder value.

Is SCPH a good stock to buy?

Whether SCPH is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the SCPH MoonshotScore?

The MoonshotScore for SCPH is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is SCPH data updated?

SCPH stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to SCPH is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for SCPH?

Growth catalysts for scPharmaceuticals Inc. (SCPH) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes scPharmaceuticals Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are SCPH's main competitors?

scPharmaceuticals Inc. (SCPH) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether SCPH has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about SCPH?

Wall Street analyst coverage for SCPH includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is SCPH's market cap?

Market capitalization (market cap) for SCPH is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows SCPH's current market cap alongside enterprise value and other valuation metrics.

How has SCPH stock performed recently?

SCPH's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing SCPH's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in SCPH?

Key risk categories for SCPH include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures SCPH's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling SCPH?

Insider trading activity for SCPH tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is SCPH a good stock for beginners?

scPharmaceuticals Inc. (SCPH) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is SCPH for first-time investors?

Every stock carries risk, including scPharmaceuticals Inc. (SCPH). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like SCPH.